IIM
AVIR icon

INTECH Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

INTECH Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.6K Sell
16,840
-16,387
-49% -$75.3K ﹤0.01% 1910
2025
Q4 		$119K Hold
33,227
– – ﹤0.01% 2125
2025
Q3 		$96.4K Sell
33,227
-11,392
-26% -$38.9K ﹤0.01% 2277
2025
Q2 		$161K Hold
44,619
– – ﹤0.01% 2161
2025
Q1 		$133K Buy
44,619
+8,630
+24% +$26.9K ﹤0.01% 2236
2024
Q4 		$121K Buy
35,989
+25,278
+236% +$84K ﹤0.01% 2168
2024
Q3 		$35.9K Buy
+10,711
New +$38.8K ﹤0.01% 2002

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

INTECH Investment Management's AVIR Position: Q1 2026 in Review

INTECH Investment Management reduced its Atea Pharmaceuticals (AVIR) stake by 49% in Q1 2026, selling an estimated $75.3K and leaving 16,840 shares worth $90.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

INTECH Investment Management first reported a position in AVIR in Q3 2024 and has held it in 7 quarters since. The position peaked at $161K in Q2 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • INTECH Investment Management held 16,840 shares of Atea Pharmaceuticals worth $90.6K as of Q1 2026.
  • INTECH Investment Management sold 16,387 Atea Pharmaceuticals shares in Q1 2026, an estimated $75.3K.
  • Atea Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1910 holding.
  • INTECH Investment Management first reported a position in Atea Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • INTECH Investment Management's Atea Pharmaceuticals position peaked at $161K in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.